Press release
Liquid Biopsy in Cancer Diagnostics Market Growth, Trends, Consumer Demand and Key Opportunities
Liquid Biopsy in Cancer Diagnostics Market
Cancer diagnostics has entered a transformative era with the rise of liquid biopsy, a minimally invasive technique that analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from body fluids such as blood. Unlike traditional tissue biopsies, liquid biopsy enables early cancer detection, real-time monitoring, and personalized treatment selection.
As cancer incidence continues to rise worldwide, demand for non-invasive, accurate, and rapid diagnostic solutions is accelerating. Liquid biopsy technologies are at the forefront of precision oncology, offering clinicians tools to guide treatment decisions, monitor resistance, and improve patient outcomes. With increasing regulatory approvals, robust R&D pipelines, and expanding applications, the market is poised for significant growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71628
Market Overview
The global liquid biopsy in cancer diagnostics market was valued at USD 4.5 billion in 2024 and is projected to reach USD 15.6 billion by 2034, expanding at a CAGR of 13.2% during the forecast period.
Key Highlights:
• Growing preference for non-invasive diagnostics over surgical tissue biopsies.
• Expanding applications in early detection, minimal residual disease (MRD) monitoring, and therapy selection.
• Increasing adoption in both developed and emerging healthcare markets.
• Rising investment in R&D and commercialization by leading biotech and diagnostic companies.
Segmentation Analysis
By Biomarker Type
• Circulating tumor cells (CTCs)
• Circulating tumor DNA (ctDNA)
• Exosomes and extracellular vesicles
• Others (proteins, RNA)
By Technology
• Next-generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• Digital PCR
• Microarray-based assays
• Others
By Application
• Early cancer detection
• Therapy selection and companion diagnostics
• Prognosis and recurrence monitoring
• Minimal residual disease (MRD) detection
• Others
By Cancer Type
• Lung cancer
• Breast cancer
• Colorectal cancer
• Prostate cancer
• Melanoma
• Others (pancreatic, ovarian, etc.)
By End-User
• Hospitals and oncology clinics
• Reference laboratories
• Research institutes
• Pharmaceutical and biotech companies
Segmentation Summary:
ctDNA-based tests dominate current adoption, particularly in lung, breast, and colorectal cancers. NGS platforms are increasingly critical, providing high sensitivity for early detection and MRD monitoring. Pharmaceutical and biotech companies are also leveraging liquid biopsy for drug development and companion diagnostics.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71628/liquid-biopsy-in-cancer-diagnostics-market
Regional Analysis
North America
• Largest market share, driven by early technology adoption, strong reimbursement frameworks, and FDA approvals.
• The U.S. leads due to its robust biotech ecosystem and extensive clinical research networks.
Europe
• Significant growth supported by government-backed cancer screening programs and adoption of personalized medicine.
• Germany, France, and the UK are primary contributors.
Asia-Pacific
• Fastest-growing region, with rising cancer incidence and investments in molecular diagnostics.
• China, Japan, and India are emerging as major markets, with increasing clinical trial activity.
Middle East & Africa
• Gradual adoption of advanced diagnostics, with growing focus on cancer detection programs.
• Infrastructure and affordability remain challenges.
Latin America
• Brazil and Mexico lead adoption, supported by expanding healthcare access and international collaborations.
Regional Summary:
North America and Europe dominate the market today, while Asia-Pacific is projected to achieve the fastest CAGR through 2034 due to its large patient pool, expanding healthcare infrastructure, and growing demand for precision oncology.
Market Dynamics
Key Growth Drivers
• Rising global cancer burden requiring advanced diagnostic tools.
• Preference for minimally invasive methods over surgical biopsies.
• Expansion of applications in therapy selection, MRD monitoring, and recurrence detection.
• Strong R&D investments and collaborations between diagnostic companies and pharma firms.
Key Challenges
• High costs of liquid biopsy tests compared to conventional diagnostics.
• Limited awareness and adoption in low- and middle-income countries.
• Technical challenges related to sensitivity and specificity of assays.
Latest Trends
• Development of multi-cancer early detection (MCED) tests capable of identifying multiple cancers from a single sample.
• Integration of AI and bioinformatics for enhanced biomarker analysis.
• Expansion of companion diagnostics linked to targeted therapies and immunotherapies.
• Growing use of real-world evidence (RWE) to validate test effectiveness in diverse populations.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71628
Competitor Analysis
Leading Market Players
• Guardant Health, Inc.
• Foundation Medicine, Inc. (a Roche company)
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• Agilent Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Exact Sciences Corporation
• Natera, Inc.
Competitive Summary:
The market is competitive, with Guardant Health, Foundation Medicine, and Illumina leading through innovative ctDNA-based solutions. Natera and Exact Sciences are expanding applications in MRD monitoring and colorectal cancer screening. Strategic partnerships, regulatory approvals, and multi-cancer early detection initiatives are key factors driving competition.
Conclusion
The liquid biopsy in cancer diagnostics market is projected to grow from USD 4.5 billion in 2024 to USD 15.6 billion by 2034, at an impressive CAGR of 13.2%.
Key Takeaways:
• Liquid biopsy is revolutionizing cancer care with non-invasive, precise diagnostics.
• ctDNA and NGS-based assays are driving current adoption, with MRD and early detection as growth frontiers.
• North America and Europe lead today, while Asia-Pacific is set to grow fastest through 2034.
• Cost and technical challenges remain but are being addressed through innovation and scaling.
This report is also available in the following languages : Japanese (がん診断市場における液体生検), Korean (암 진단 시장의 액체 생검), Chinese (癌症诊断市场中的液体活检), French (Biopsie liquide sur le marché du diagnostic du cancer), German (Flüssigbiopsie im Markt für Krebsdiagnostik), and Italian (Biopsia liquida nel mercato della diagnostica del cancro), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71628
Our More Reports:
Radiopharmaceuticals Market
https://exactitudeconsultancy.com/reports/72413/radiopharmaceuticals-market
Veterinary Vaccines Market
https://exactitudeconsultancy.com/reports/72412/veterinary-vaccines-market
Lipid Nanoparticle Manufacturing Market
https://exactitudeconsultancy.com/reports/72416/lipid-nanoparticle-manufacturing-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liquid Biopsy in Cancer Diagnostics Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4173845 • Views: …
More Releases from Exactitude Consultancy
Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market is expected to reach $6. …
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, accounting for approximately 15% of all lung cancer cases worldwide. It is characterized by rapid tumor growth, early metastasis, and poor long-term survival. Among SCLC patients, nearly two-thirds are diagnosed with extensive-stage disease (ES-SCLC), where the cancer has spread beyond the lungs, making curative treatment nearly impossible.
Download Full PDF Sample Copy of Market Report @…
PD-L1 Inhibitors Market Growth, Applications, Innovations and Business Outlook b …
Introduction
Immunotherapy has revolutionized cancer treatment, with Programmed Death-Ligand 1 (PD-L1) inhibitors emerging as one of the most transformative breakthroughs in oncology. By blocking the PD-1/PD-L1 immune checkpoint pathway, these drugs restore the body's ability to recognize and attack tumor cells. Their adoption has dramatically changed the prognosis for patients with melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and other solid tumors.
The global PD-L1 inhibitors market is entering a…
Metastatic HER2+ Breast Cancer Patient Pool Analysis Market is expected to reach …
Breast cancer remains the most common cancer among women globally, and approximately 15-20% of all cases are classified as HER2-positive (HER2+), characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. While targeted therapies such as trastuzumab, pertuzumab, and newer antibody-drug conjugates (ADCs) have significantly improved outcomes, metastatic HER2+ breast cancer (mHER2+ BC) continues to present clinical challenges due to disease progression, resistance to therapy, and limited…
Anaplastic Thyroid Cancer (ATC) Market Growth, Applications, Innovations and Bus …
Introduction
Anaplastic thyroid cancer (ATC) is one of the rarest but most aggressive forms of thyroid cancer, accounting for less than 2% of thyroid cancer cases yet responsible for a disproportionately high mortality rate. Characterized by rapid progression, local invasion, and resistance to conventional therapies, ATC has historically posed significant treatment challenges.
In recent years, however, advances in targeted therapies, immunotherapy, and molecular diagnostics have created new opportunities to improve outcomes for…
More Releases for DNA
High-Quality Plasmid DNA Fuels Growth in Global DNA Plasmid Manufacturing Market
🌍 Market Overview
The DNA Plasmid Manufacturing Market is experiencing robust growth as advancements in cell & gene therapy, DNA vaccines, and genetic engineering continue to expand globally. Plasmid DNA plays a critical role as a raw material in the development of advanced therapies, fueling demand across biopharmaceutical research and production.
Key factors driving the market include:
Increasing adoption of gene and cell therapies
Rising prevalence of chronic and rare genetic disorders
Expansion of DNA-based…
DNA Synthesis Market Increasing Demand for Synthetic Genes and DNA Sequences
As demonstrated by Precision Business Insights (PBI), the latest report, the global DNA synthesis market was valued at USD 3,702.0 million in 2023 and is expected to reach USD 10,289.5 million by 2029, growing at a CAGR of 18.6% during the forecast period 2024-2030. The key drivers for the growth of the global DNA synthesis market include increasing demand for synthetic genes and DNA sequences, growing applications in the agriculture…
Wealth DNA Code Review Legit Price? (Wealth Manifestation DNA Code Audio Frequen …
Wealth DNA Code Wealth DNA Code is a digital program with seven minutes of soundtracks that manifest and listen to daily to activate the "Wealth DNA," which is part of your DNA to help you attract wealth by making money a part of your mentality and making your dreams to come true.
https://bit.ly/Visit-The-Official-Website-Here-To-Order-Wealth-DNA-Code
Making money, creating assets as well as increasing wealth are the primary objectives that every human being has to…
DNA Paternity Testing Market Size [2022-2029] -DNA Diagnostics Center, EasyDNA, …
A recent market research report added to repository of MR Accuracy Reports is an in-depth analysis of global DNA Paternity Testing. On the basis of historic growth analysis and current scenario of DNA Paternity Testing place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent…
DNA Paternity Testing Market Trends 2020 | Growth by Top Companies: DNA Diagnost …
The report begins with the overview of the DNA Paternity Testing Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behaviour, pricing factors and market performance and estimation. The forecast market information, SWOT analysis, DNA Paternity Testing market scenario, and feasibility study are…
DNA Paternity Testing Market Rapidly Growing in Healthcare, Competitor Analysis …
The exclusive research report on the Global DNA Paternity Testing Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global DNA Paternity Testing Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.
Overview of Global DNA Paternity Testing Market:
This report studies the Global DNA Paternity Testing…
